Biocartis Group NV
Develops and commercializes an automated molecular diagnostics platform for oncology.
BCART | BR
Overview
Corporate Details
- ISIN(s):
- BE0974281132 (+1 more)
- LEI:
- 549300J4HOJL5KG8HY54
- Country:
- Belgium
- Address:
- GENERAAL DE WITTELAAN 11 BOÎTE B, 2800 MECHELEN
- Website:
- https://www.biocartis.com/en
- Sector:
- Manufacturing
Description
Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-31 07:00 |
biocartisgroup-2021-12-31-nl.zip
|
Dutch | 818.2 KB | ||
| 2022-03-31 07:00 |
biocartisgroup-2021-12-31-nl.xhtml
|
Dutch | 2.5 MB | ||
| 2022-02-24 07:00 |
220223 PR_Biocartis FY21 results_ENG_FINAL.pdf
|
English | 359.7 KB | ||
| 2022-02-24 07:00 |
220223 PR_Biocartis FY21 results_NL_FINAL.pdf
|
Dutch | 365.5 KB | ||
| 2022-02-04 07:00 |
220203 Transp Notif Credit Suisse.pdf
|
Dutch | 740.6 KB | ||
| 2022-02-04 07:00 |
220203 PR TranspNotification_Credit Suisse_ENG_FINAL.pdf
|
English | 75.4 KB | ||
| 2022-02-04 07:00 |
220203 PR TranspNotification_Credit Suisse_NL_FINAL.pdf
|
Dutch | 76.8 KB | ||
| 2021-11-10 07:00 |
211109 Biocartis Q3 2021 Business Update_ENG_FINAL.pdf
|
English | 135.6 KB | ||
| 2021-11-10 07:00 |
211109 Biocartis Q3 2021 Business Update_NL_FINAL.pdf
|
Dutch | 137.6 KB | ||
| 2021-10-12 07:00 |
211011 TranspNotif_CreditSuisseIII_Biocartis_FINAL.pdf
|
English | 764.7 KB | ||
| 2021-10-12 07:00 |
211011 PR TranspNotificationIII_Credit Suisse_ENG_FINAL.pdf
|
English | 75.9 KB | ||
| 2021-10-12 07:00 |
211011 PR TranspNotificationIII_Credit Suisse_NL_FINAL.pdf
|
Dutch | 77.1 KB | ||
| 2021-09-13 17:40 |
210902 TranspNotif_CreditSuisse_II_Biocartis.pdf
|
English | 475.0 KB | ||
| 2021-09-13 17:40 |
210913 PR TranspNotification_Credit Suisse_ENG_FINAL.pdf
|
English | 76.2 KB | ||
| 2021-09-13 17:40 |
210913 PR TranspNotification_Credit Suisse_NL_FINAL.pdf
|
Dutch | 77.3 KB |
Automate Your Workflow. Get a real-time feed of all Biocartis Group NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biocartis Group NV
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biocartis Group NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-04-29 | Devogelaere Benoit | Executive member | Buy | 15,000 | N/A |
| 2021-04-28 | Marcofin BV | Executive member | Buy | 30,000 | N/A |
| 2021-04-27 | Herman Verrelst | Board | Buy | 60,000 | N/A |
| 2020-11-13 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2020-05-06 | Herman Verrelst | Board | Buy | 50,000 | 249,625.00 EUR |
| 2020-05-06 | Herman Verrelst | Board | Buy | 300,000 | N/A |
| 2020-05-04 | Herman Verrelst | Board | Buy | 46,803 | 231,656.00 EUR |
| 2020-05-04 | Herman Verrelst | Board | Buy | 3,197 | 15,315.00 EUR |
| 2019-12-18 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2019-12-16 | Welten Ewoud | Executive member | Buy | 10,000 | N/A |
Peer Companies
